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Nanotechnology has recently emerged as a strong contributor toward research efforts to develop 
targeted systems of drug delivery in cancer therapy.  Our work investigates the therapeutic 
potential of Targeted Charge-Reversal Nanoparticles (TCRNs), a novel nanoparticle with in vitro 
evidence of nuclear drug delivery. Using M12 prostate cancer cells, MDA-MB-231 breast cancer 
cells, and modified derivatives of these cell lines, we investigated the ability of Folic Acid-
tagged TCRNs to deliver Nile Red and Dimethyl Indole Redfluorescent (DiR) fluorescent dyes 
to the nucleus of cells using confocal microscopy and in vivo biphontonic imaging using 
Xenogen® Technology. Confocal imaging with the SCP28 derivative of MDA-MB-231 cells 
shows nuclear association of the TCRNs over time, although specific nuclear deposition was 
unclear. Biophotonic imaging with M12 and SCP28 xenograft tumors in athymic nude mice 
shows retention of TCRNs in animals out to 7 days with minimal localization of TCRNs to 
tumor tissues. Our findings suggest that further characterization and manipulation of both the 
cells and the nanoparticle is necessary in order to make definitive claims regarding the TCRN’s 
ability to deliver fluorescent dyes, and eventually therapeutic compounds, to the nucleus of cells. 
 Chapter 1 
Introduction 
 
Cancer Therapy 
The Centers for Disease Control report that cancer claims the lives of more than half a 
million Americans every year. Cancer is the second leading cause of death in the United States, 
exceeded only by heart disease. Of the various cancers detected in the USA, cancers of the breast 
rank highest in women and cancers of the prostate rank highest in men (1). The search for 
therapies for all forms of cancer continues with limited success. Traditional approaches in cancer 
treatment have focused on killing all actively dividing cells whether or not they were cancer or 
normal cells. Further advances have resulted in developing therapies that target destruction of the 
cancer while minimizing damage to healthy tissues and cells. Historically, drug and radiation 
cancer therapies predominate but advances are frustrated by significant patient toxicities and side 
effects due to lack of specificity (2). Various attempts have been made to address these problems 
with variable success, indicating a need to investigate novel systems for drug delivery that can 
circumvent adverse patient reactions while retaining high levels of drug toxicity that target the 
rapidly dividing cancer cells.  
 
Nanotechnology 
Engineers refer to Nanoparticles (NPs) as structures that are measured in the nanometer 
range (generally less than 100 nm in diameter) (3). In recent years, the field of Nanotechnology 
has produced many advances that use NPs with applications in medicine, including aids in 
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diagnostics, biomimetic and biohybrid systems, and therapeutics that employ novel drug delivery 
techniques. Recently, many promising nanotherapeutics for drug delivery have been developed, 
many of which have successfully delivered therapeutic agents in vitro (3-5). These 
nanostructures can be loosely categorized based on their chemistry and structure. Liposomes, for 
example, are small vesicular structures generally composed of a phospholipid bi-layer with an 
aqueous core. This structural arrangement confers properties to the NP that are similar to those of 
cell membranes. Liposomes can be loaded with drugs and used to deliver compounds to treat 
cancer and other diseases. Similar to liposomes are polymeric micelles, which make use of 
organic polymeric structures usually in a uni-layer, spherical configuration. Fullerenes and 
nanotubules are structurally and functionally similar hollow structures that can also potentially 
be used to carry drugs, although they are more rigid and are typically composed of carbon, metal 
(gold or silver), or silicon. Quantum dots are smaller, charged, solid spheres that are typically 
used for bioimaging, for carrying drugs that can be tagged to their surface, and for carrying 
highly charged materials. Examples of these nanoparticle structures are shown in Figure 1. More 
elaborate nanotechnologies are being developed that modify and use these basic structures in 
various combinations (6-7). 
The use of NPs in medicine, while promising, is not without significant challenges. 
Previous studies show that depending on the starting material, the NP is prone to elimination via 
the body’s natural immune system primarily through phagocytosis by macrophages (8-10). 
Additionally, once NPs enter a living organism, they must fight against an array of natural host 
defenses and changes in the microenvironment that can result in their elimination or in the 
premature release of their therapeutic contents, ultimately leading to the same toxic side effects 
that arise from therapeutic agents delivered by more conventional means. Assuming that NP- 
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Dendrimers
Nanodots Nanotubes
Liposomes/Micelles
 
 
Figure 1:  Basic Nanoparticle Structures. Nanoparticles have been designed using these basic 
structures alone or in combination with each other. Shown above are the regularly branched 
Dendrimer structure, the spherical Liposomes/Micelle structure, the solid and charged Nanodot 
structure, and the hollow Nanotubule/Fullerene structure.  
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carrying drugs are able to survive the host’s immune system, it then needs to retain and deliver 
the therapeutic agent to the targeted tissue or body system. Through all of these challenges, the 
NPs must circumvent obstacles related to water or fat solubility, membrane permeability, pH 
alterations, cell surface receptor interactions, and charge limitations, all of which affect the NP’s 
ability to retain the effectiveness of its therapeutic agent (3, 7). The NP that survives host 
defenses, that retains its therapeutic agents, and that selectively targets cancer cells for delivery 
of their contents will be a powerful asset in cancer therapy. Such a targeted NP would 
theoretically reduce patient toxicity by reducing the dosage of the therapeutic agent while, at the 
same time, still concentrating the agent and its effect at the site of the cancer.  
Despite these challenges, nanotechnology is still a promising alternative to conventional 
drug delivery.  Studies with liposomes, polymeric micelles and nanotubules show results 
indicating successful delivery of different therapeutic agents to cells especially under in vitro 
conditions (3-4, 11-12). While some NP-mediated therapies have begun to enter clinical trials (6, 
13-15), most NPs have shown very limited success for drug delivery in vivo due, in part, to the 
aforementioned fact that once the NPs are introduced into a living organism, they are subject to 
natural host defenses and microenvironment changes that result in their elimination or in a 
premature release of their therapeutic contents (3, 16). If NPs could target not only the cell but 
the nucleus of the cell, this could potentially magnify a drug’s therapeutic potential 
exponentially. The focus of our study was to investigate the therapeutic potential of the Targeted 
Charge-Reversal Nanoparticles (TCRNs) to deliver agents to the nucleus of breast and prostate 
cancer cells.   
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Targeted Charge-Reversal Nanoparticles  
TCRNs are unique NPs, and studies suggest they can successfully deliver 
chemotherapeutic agents to the nucleus of human ovarian carcinoma cells (SKOV-3) in vitro (11, 
17). The TCRNs are based on a polymeric micellar system that has been developed by Dr. 
Youqing Shen at the University of Wyoming. Dr. Shen is a noted polymer chemist with 
significant experience in generating NPs for specific delivery of compounds to the nucleus of 
eukaryotic cells. The NP used for our experiments is constructed using 3 different polymers that 
combine to form a pH-responsive structure, which has the potential to deliver drug past the 
cytoplasm into the nucleus of the cell. The NP is made up of a negative-to-positive charge-
reversal polyethyleneimine (PEI) polymer outer layer that responds to pH changes, which is only 
triggered at specific locations related to the cell. The TCRNs reportedly undergo a 
conformational change during exposure to the extracellular acidic environment (pH<7), which is 
often found around inflamed or neoplastic tissues and within the acidic lysosomal environment 
(pH 4–5) during cell entry (11, 17). In general, negatively charged polymers have little 
interaction with blood components, so the PEI polymer has been used extensively in vivo for this 
purpose (3, 18). There is a second hydrophobic polymer, polycaprolactone (PCL), joined with 
the PEI that together combines to stimulate the formation of the micellar system responsive to 
changes in pH.  Previous experiments (19) showed that the micelles formed by this polymer 
combination, when linked with a FA moiety (the third component of the terpolymer), can 
navigate the pH shifts in blood, tumor, and intracellular liposomal environments in such a way as 
to carry drug to the nucleus of the cell (Figure 2). These in vitro results found that TCRNs 
carrying doxorubicin (DOX) are more effective at killing SKOV-3 cancer cells than free DOX 
alone (11). If this experiment can be duplicated using other cell lines while carrying different 
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Figure 2:  Schematic representation of the movement of TCRNs into the cell. TCRNs 
move out of vascular circulation into the tumor microenvironment where they undergo pH and 
charge alterations that permit them to move into the cell to deposit their contents into the 
nucleus. Image used with permission (Dr. Youqin Shen). 
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therapeutic agents in both in vitro and in vivo systems, then this TCRN system could have major 
therapeutic implications for many cancer types.  
For our studies, TCRNs were conjugated with folic acid (FA) to employ the folate 
receptor (FR) as a target for attachment to and entry into the cell. FAs (also known as 
pteroylglutamic acid, vitamin B9, Bc folacin, and folate) are essential cofactors for many 
biochemical reactions involving one-carbon metabolism, including purine and thymidine 
synthesis, remethylation of homocysteine to methionine, and conversion of serine to glycine. The 
role of this vitamin in the production of precursors for DNA synthesis and repair makes it 
essential for proliferating cells (20-21). The high affinity FR is a membrane-associated 
glycoprotein that is preferentially expressed in cancers of epithelial origin (20, 22-23), which 
makes it an ideal candidate for many novel targeted drug therapies and is the focus of many NP 
driven studies (4, 21, 24).  
FAs are used in many cellular processes, but the hydrophilic and anionic nature of FAs, 
at physiologic pH, impedes their passive diffusion through the plasma membrane. Therefore, 
most cells acquire the FA needed for normal cell processes primarily by two separate 
mechanisms. One involves a transmembrane transporter, known as the reduced folate carrier 
(RFC), named because of its inability to bind FA, the nonphysiologic, oxidized form of the 
vitamin. This ubiquitously expressed RFC protein has a high affinity for 5-
methyltetrahydrofolate (5-MTHF) (Kd 3– 4.0µmol/L), which is the predominant FA formulation 
found in serum although it has a much lower affinity for FA (Kd 5 100–200µmol/L). The RFC is 
also present throughout development and in normal adult tissues, despite significant variability in 
its expression levels among tissue types (25-26).  
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The other primary FA uptake system uses a glycosyl-phosphatidylinositol (GPI)-
anchored protein known as the FR that transports FAs into the cytosol via fluid-phase 
endocytosis. The physiologic function of the FR in adult tissues has largely remained a mystery 
since, in addition to its narrow tissue distribution, the FR is predominantly expressed on the 
apical (luminal) surface of polarized epithelial cells, where it is not in contact with circulating 
FA. This FR binds its ligands with very high affinity, having a Kd of 0.4nmol/L for FA and 
3nmol/L for 5-MTHF (25-27).  
There are four isoforms of the FR (FRs −α, −β, −γ and −δ ) that vary somewhat in 
sequence, ligand preference, and tissue distribution, such that only one isoform, designated FR-α, 
is thought to be physiologically relevant with respect to the targeting of solid tumors in therapy 
because of its tendency to be over expressed in many tumor types (20). FR-α and FR-β are 
membrane-associated proteins, whereas FR-γ lacks the signal for GPI-anchor attachment and is 
constitutively secreted (27-28). FR-β has some clinical relevance as it is expressed in later stages 
of normal myelopoiesis and in placenta, spleen, and thymus. FR-β is also expressed in leukemic 
blasts in chronic and acute myelogenous leukemia (27). Because we focused primarily on the 
function of the FR-α in our cells, unless stated otherwise, all references to the FR will signify the 
more physiologically relevant FR-α. 
As stated, the FR is expressed at the luminal surface of polarized epithelial cells of 
normal adult tissues including proximal kidney tubules, type I and II pneumocytes in the lungs, 
choroid plexus, ovary, fallopian tube, uterus, epididymis, submandibular and bronchial salivary 
glands, and trophoblasts in placenta, as well as the basolateral membrane of retinal pigment 
epithelial cells (25). Several malignant tumors are known to overexpress FR, including non-
mucinous adenocarcinomas of the ovary, uterus and cervix, testicular choriocarcinoma, 
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ependymal brain tumors, malignant pleural mesothelioma, and nonfunctioning pituitary 
adenocarcinoma. In other malignant types of cancer such as breast, colon, and renal cancers, FR 
over-expression is less frequent but still common enough to be exploited (27-28)  While virtually 
every potential drug target protein in malignant cells is also expressed in at least a few critical 
normal tissues, this differential anatomic distribution of FR renders it generally inaccessible 
directly through the blood stream in normal tissues, making it a preferred target to effectively 
address the problem of tumor specificity. Moreover, the receptor specifically and tightly binds a 
small water soluble molecule, FA, that is amenable to chemical conjugation of small and large 
drug molecules or nanoparticles without disruption of its binding properties (18, 27).  
In vitro studies suggest that the TCRN NPs attach to cells using the FR and then are later 
brought into the cell via endocytosis (Figure 2) (11, 17). The proposed mechanism for this 
attachment hinges on the metabolic and inflammatory processes that occur near the actively 
growing tumor and the increased vascular permeability in the tumor microenvironment. It is 
hypothesized that when the blood borne negatively charged TCRN carrying drug circulates near 
this weakly acidic microenvironment, it extravasates, becomes positively charged, and is 
internalized within the cell either by receptor-mediated endocytosis or by adsorptive endocytosis 
(endosome). Once the NP gains entry into the cell by either mechanism, it is transferred to the 
strongly acidic lysosome where the PEI/amide outer layer is hydrolyzed into PEI, the NP 
undergoes a conformational change, and the modified TCRN is then released from the lysosome 
to subsequently enter the nucleus for drug delivery (11, 17).  
In this study, we aim to verify this claim in additional cell lines and to confirm that 
TCRNs are actually able to target and deliver fluorescent dyes to breast and prostate cancer cells 
in an in vitro environment.  Further, we hope to show that these TCRNs are also uniquely able to 
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deliver fluorescent dyes, not simply to the cytoplasm, but to the nucleus of breast and prostate 
cancer cells. Our central assertion is that TCRN’s are capable of delivering fluorescent agents to 
the nucleus of carcinoma cells. TCRN delivery can be manipulated by exploiting pH changes in 
the microenvironment of the cell and by utilizing the cell surface FR as a mechanism for cellular 
delivery in an in vivo and an in vitro environment.   
 
Fluorescent Imaging 
This study makes use of several imaging technologies, all of which are based on the same 
fundamental principles that govern our ability to see light. Photons that strike objects are 
reflected or absorbed, creating a signal that registers on an image transducer. The vertebrate 
retina, which absorbs and transduces photon signals to the brain producing an image, is the 
simplest example of this principle. Engineers take this basic principle and translate it into 
technology that permits visualization of things that are not visible with the unaided eye. We can 
visualize internal organs macroscopically using technologies that manipulate sound (ultrasound 
imaging), X-ray radiation (radiographic imaging), and ionizing radiation (magnetic resonance 
imaging). On a microscopic level, manipulating electrons and lasers helps us to magnify images 
that are beyond the ability of ordinary light microscopes. All of these technologies can be further 
enhanced using contrasting agents that further amplify or modify the signal being recorded. 
Radiography, for example, uses barium or iodine contrast agents to improve visualization of 
organs, while microscopy uses fluorescent agents to improve visualization of cellular structures 
and organelles (29-30).  
In our study, we use optical fluorescent imaging technology and Xenogen Imaging 
Technology (XIT) to confirm the ability of the TCRNs to deliver their contents to the cell. 
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Confocal microscopy is an advanced form of light microscopy, useful for viewing fluorescently 
labeled cellular structures. An object of interest is labeled or tagged with a fluorophore that, 
when illuminated with light of a specific wavelength, will absorb the light and emit a signal at 
another longer wavelength that is detected by the optical imaging device and transmitted as 
color. Confocal microscopy uses this same principle with light generated by lasers of different 
wavelengths that scan the sample in a more focused manner. The illumination is confined to a 
diffraction-limited spot in the specimen and the detection is similarly confined. All of this 
produces an ‘optical sectioning’ effect, in which the glare from out-of-focus regions is almost 
completely eliminated and the image sharpened (31).  
Bioluminescent in vivo imaging using XIT, also known as biophotonics, employs similar 
principles to image macroscopic objects in real time. This in vivo imaging is a noninvasive 
technique using bioluminescent and fluorescent endogenous reporters or exogenous probes to 
monitor molecular and biological processes. In the simplest terms, it is a device with a sensitive 
camera that measures light produced by biological or chemical moieties. The object being 
imaged is placed on the sample stage where the fluorescent signal passes through the animal to 
the lens and filters and, ultimately, to the camera. The light is detected by the sensitive camera 
and superimposed over a normal camera image of the animal/object (Figure 3). It is a non-
invasive time/space visualization of biological processes inside of a live animal, relying on light 
producing optical reporters such as luciferase, fluorescent proteins, fluorescent dyes and 
conjugates. Genes encoding luciferase and fluorescent proteins can be engineered into cells (e.g., 
cancer cell lines and infectious disease agents) and into animals (transgenic mice and rats), 
which enables them to produce light that can then be visualized through the tissues of a live 
animal using specialized Xenogen imaging equipment and software (30, 32). Most commonly, 
12 
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Figure 3:  IVIS® Spectrum Imaging System. On the left is the Xenogen machine positioned 
next to its anesthesia vaporizer and computer for image analysis. On the right is a schematic of 
the machine’s internal imaging components. Image is courtesy of Caliper Life Sciences. 
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the imaging device measures luminescent signals that are produced when natural biological 
substances, typically luciferin or green fluorescent protein (GFP), are injected into or otherwise 
expressed in animals and excited by a substrate-driven enzymatic processes to produce light at 
different wavelengths. Similarly, the device can be used with fluorophores or fluorescent 
reporters that come in a wider variety of forms: expressed proteins, dyes, microspheres, and NPs. 
Visualization of fluorescent reporters does not require the administration of a substrate and can 
be used in both live and fixed cells/tissues (29). This highly sensitive dual bioluminescence and 
fluorescence imaging systems has the advantage of allowing significantly fewer animals to be 
used due to the fact that the entire process is non-invasive. Additionally, this technology allows 
us to follow the development of tumors and to monitor the intensity of any fluorescent signal 
present in the tumor over time in the live animal. The final image produced by XIT is a 
composite image composed of a photographic image of the object superimposed over a 
luminescent image with intensity of luminescence represented by gradations in color (Figure 4).  
In this study, we aimed to verify the nuclear delivery claims of the TCRNs by integrating 
a fluorescent dye into the core of the NP and working to show that this dye is being deposited 
into our cells. Our goal was to show that the dye is ultimately deposited in the nucleus of cancer 
cells, suggesting that the TCRNs will function similarly when carrying chemotherapeutic agents. 
In so doing, we expected to demonstrate by proof of principle the potential use of TCRNs for 
delivery of therapeutic agents into cells, further suggesting that TCRNs can be used to reduce the 
dosage of chemotherapeutic agents that often target the DNA machinery in the nucleus and are 
highly toxic to patients.  
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Figure 4:  Construction of the Xenogen Image. Standard images are composed of two 
superimposed images: Photographic image + Luminescent image = Overlay image.  These are 
screen shot images of what is seen when measurements are taken using the Xenogen imager. 
Image is courtesy of Caliper Life Sciences. 
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The overall hypothesis and specific aims are as follows: 
 
Hypothesis: We propose that TCRNs carrying fluorescent dyes will selectively deposit their 
contents into the cytoplasm and the nucleus of carcinoma cells using the FA/FR interaction 
producing changes in fluorescent signaling as observed by in vitro and in vivo assays. 
  
Specific Aim: To characterize and verify the FR profile of our prostate and breast cancer cell 
lines in order to 1) demonstrate TCRN dye delivery and 2) correlate TCRN function with the FR 
using differences in fluorescent signaling within the cytoplasm and the nucleus of tumor cells.  
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 Chapter 2 
Materials and Methods 
 
Cell Lines and Culturing: Several cell lines were used for this study: M12 prostate cancer cells; 
M12-luc cells, which are prostate cancer cells stably transfected to express luciferase; MDA-
MB-231 breast cancer cells; SCP28-S4-Tet-Duo breast cancer cells, which are also engineered to 
express luciferase; BJ foreskin fibroblast (BJF); and adipose derived stem cells (ASC).  BJ 
fibroblasts were grown in high glucose Dulbecco's modified Eagle's medium (DMEM; 
Invitrogen) supplemented with 10% cosmic calf serum (Hyclone) and 1% 
Antibiotic/Antimycotic Solution (ABAM; Sigma-Aldrich). ASC-8 at PD10 were previously 
isolated in our laboratory from a lipoaspirate obtained from the VCU Surgery Department in 
accordance with VCU IRB procedures for medical waste.  ASC-8 cells were grown in low 
glucose DMEM supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% ABAM. 
Both the M12 and the M12-luc cells were cultured in Roswell Park Memorial Institute (RPMI; 
Invitrogen) medium supplemented with 0.03mg/ml gentamicin+ 0.3mg/ ml L-glutamine + 0.1% 
ITS (Insulin/Transferrin/Selenium; VWR Radnor, PA) + 5% FBS. MDA-231 and SCP28-S4-
Tet-Duo breast cancer cells were cultured in RPMI medium supplemented with 0.03mg/ml 
gentamicin + 0.3mg/ml L-glutamine + 5% FBS. 
The principle cell lines used for all of the experiments are the M12 and M12-luc prostate 
cancer cell line, and the MDA-MB-231 and SCP28 breast cancer cell lines. The M12 cell line is 
a tumorigenic, metastatic subline of human prostate epithelial cells previously immortalized by 
transfection with the SV40T antigen gene, developed by Dr. Joy Ware by sequential passage of 
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the cells in male athymic nude mice (33). The SCP is a single cell-derived subline of MDA-MB-
231 that is highly osteolytic and metastatic, but it is also engineered for bioluminescent imaging. 
This cell line was engineered to express Renilla luciferase under a constitutively active 
cytomegalovirus promoter for quantitative measurement of metastatic tumor burden in vivo 
through noninvasive bioluminescence imaging using coelanterazine as the substrate. It also 
expresses firefly luciferase using D-luciferin as the substrate (34). 
 
Western Blot Analysis: To confirm the presence of the FR in M12, M12-luc, MDA-231, BJF, 
and ASC cells, we performed Western analysis for FR and β-actin (as an internal control). Cells 
were trypsinized and then lysed with Radio-Immunoprecipitation Assay (RIPA) buffer 
supplemented with protease inhibitor (Sigma) for 30mins on ice. Whole cell lysates were 
prepared from each of these cell lines and subjected to five 20 second pulse intervals of 
sonication at power level 2 using a Misonix 3000 sonicator in order to shear the genomic DNA 
prior to gel electrophoresis. The samples were placed on ice between treatment intervals. After 
sonication, lysates were clarified by centrifugation at 11,000 x g for 20mins.  The resulting 
supernatant was collected and analyzed for total protein content using a Biorad Protein Assay kit 
and a spectrophotometer. Protein samples were treated with non-reducing 4x sample buffer (4% 
SDS, 20% glycerol, 0.004% bromophenol blue, 0.125M Tris HCl, at pH 6.8) at 85°C for 10mins 
and then loaded (25μg total protein per sample) on a 10% sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE) followed by electrophoresis for approximately 1.5 hours.  
Following SDS-PAGE, the gel was transferred to nitrocellulose membrane by electroblotting at 
100 volts for approximately 1 hour.  The membrane was blocked using 5% non-fat milk for 1 
hour at room temperature, followed by multiple washes with PBS+1% Tween-20 (PBS-T). The 
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blot was incubated with primary antibodies (anti-folate, at 5µg/ml; Enzo Life Sciences; anti-β-
actin at 1μg/ml; Sigma) for 1 hour at room temperature, followed by multiple PBS-T washes.  
Secondary antibody (goat anti-mouse conjugated to horseradish peroxidase, at 1µg/ml dilution; 
#172-1011 BIO-RAD, Hercules CA) was used to probe the blot for 1 hour at room temperature, 
followed by extensive washing with PBS-T.  Pierce SuperSignal (luminol and peroxide 
solutions) was used for detection, and the blot was exposed to Kodak OMAT film and 
developed. We used this non-reducing protocol because the FR is a complex cell surface protein 
whose conformation is very sensitive to reducing reagents, and our particular antibody was not 
able to recognize the FR protein after it had been treated with a reducing protocol. We needed to 
adjust the normal Western assay to eliminate exposure to reducing agents so that our primary 
antibody could recognize the protein.  
 
Fluorescence-Activated Cell Sorting (FACS) Analysis: To quantify and further characterize 
the presence of the FR on the cell surface of the M12, M12-luc, MDA and SCP cell lines, we 
used FACS analysis. The cells were cultured in cell-specific media and then harvested with 
0.25% (w/v) trypsin-0.1% (w/v) EDTA solution and counted, adding approximately 1x106 cells 
to sample tubes. The cells were incubated in FACS buffer (PBS + 1% FBS) at room temperature 
for 15mins and then on ice for 10mins. Following this stabilization period at room temperature to 
allow cell surface proteins to recover from trypsin treatment, the cell suspension was treated with 
primary mouse monoclonal antibody (anti-folate, at 5µg/ml; Enzo Life Sciences, Plymouth 
Meeting, PA) and incubated for 30mins on ice rocking gently. Cells were washed 3 times with 
FACS buffer and then treated with secondary antibody (goat anti-mouse IgG conjugated to 
Alexa 488 at 1µg/ml; A11029 Invitrogen) on ice rocking gently. Cells were washed again 3 
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times in FACS buffer and then counted in BD FACSCanto II Flow Cytometer using DIVA 
software for signal analysis.  
 
Fluorescent Microscopy: To assess the relative expression level of the folic acid receptor in 
vitro, 1x104 cells were seeded and were grown on an 8-well chamber slide to 60-70% 
confluency. The cells were rinsed twice with PBS and fixed with 4% paraformaldehyde for 
10mins at room temperature. The cells were then washed twice in PBS and permeabilized with 
0.5% NP-40.  After washing again, the cells were blocked with a mixture of Cold Water Fish 
Gelatin with BSA dissolved in PBS (PBG) for 1 hour followed by overnight incubation at 4ºC 
with primary mouse monoclonal antibody (anti-folate, at 2.5μg/ml; Enzo Life Sciences) diluted 
in PBG. The cells were then washed with PBG 3 times and treated with secondary antibody (goat 
anti-mouse IgG conjugated to Alexa 488 at 1μg/ml dilution; A11029 Invitrogen) also diluted in 
PBG. The cells were next washed 3 times in PBG and then covered with embedding media 
mixed with DAPI (Sigma-Aldrich, St. Louis, MO) and Vectashield mounting media (Vector 
Laboratories, Burlingame, CA). We used 200μg/ml of DAPI in a 1:1000 volume dilution with 
mounting media.  
 
Survival/Cytotoxicity Assay: To assay potential toxic effects of dye-loaded TCRNs, 1x104 M12 
or SCP cancer cells were seeded (~50-70% confluency) in 6-well chambers filled with 1ml of 
their respective media. The cells were allowed to acclimate and attach to the plates for 2-4 days. 
The cells were treated with TCRNs at varying concentrations for 6-168 hours.  At each time 
point (6, 24, 48, 72 and 168 hrs), cells were collected after treatment with 0.25% (w/v) trypsin-
0.1% (w/v) EDTA (Mediatech, Inc .,Manassas, VA), centrifuged, and resuspended in 2mls of 
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respective culture media. Live/dead counts were performed using a hemocytometer after Trypan 
Blue treatment (4% w/v) in normal saline (Mediatech Inc) at a dilution of 0.5mls cell suspension 
with an equal volume of 50% Trypan blue. Cell survival was evaluated at defined time intervals 
of exposure by live cell counts expressed as a percentage of total cells counted. Using Nile Red 
(NR) and Dimethyl Indole Red (DiR), cells were treated to the following dilution scheme: NR 
(PBS, 3.4µg/ml, 0.68µg/ml, 0.34µg/ml. 0.034µg/ml, and 0.0034µg/ml), DiR (PBS, 40µg/ml, 
8µg/ml, 4µg/ml, 0.4µg/ml, and 0.04µg/ml).  It should be noted here that when calculating TCRN 
doses and concentrations, one must consider both the concentration of the NP and the 
concentration of the dye contained in the NP. For the sake of simplicity, all concentrations given 
refer to the concentration of the dye contained within the NP since this would, by inference, 
represent the concentration of drug administered to the animals would. 
 
Confocal Microscopy: In 6-well chambers filled with 1 ml of respective media, 1x104 SCP cells 
or M12 cells suspended in 0.1mls of media were seeded (50-70% confluency) onto 22mm2 acid 
cleaned and flame dried cover slips. The cells were allowed to acclimate and attach to the slides 
for 2-4 days. We delivered a standard 0.1 ml volume of the various NP dilutions into 2.8ml of 
RPMI culture media in each well.  The cells were treated with the dye loaded TCRNs at various 
dye concentrations at time points ranging from 6-168 hours. At each time point, cells were fixed 
with 4% paraformaldehyde in PBS for 10mins, washed with 0.3M glycine in PBS (3x) for 
10mins, and mounted on a slide with DAPI (Sigma-Aldrich, St. Louis, MO) and Vectashield 
mounting media (Vector Laboratories, Burlingame, CA) using 200µg/ml DAPI in a  1:1000 
dilution with mounting media. Slides were stored in a light proof box at 4ºC until imaged. Cell 
imaging was performed using either a Zeiss LSM 510 META confocal microscope or the Leica 
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TCS-SP2 AOBS confocal microscope.  Images were acquired and processed with imaging 
software provided by the respective microscopes.  For our confocal imaging, we originally chose 
DiR as our fluorescent dye because it is lipophilic and easily intercalates with cell membrane 
structures. It has a higher emission spectra enabling better tissue penetration during Xenogen 
imaging.  DiR emits in a range that is near infrared fluorescence (excitation 750nm/emission 
780nm). It is also a lipophilic carbocyanine that is weakly fluorescent in water but highly 
fluorescent and quite photostable when incorporated into membranes. It has an extremely high 
extinction coefficient and short excited-state lifetimes (~1 nanosecond) in lipid environments 
(35). Once applied to cells, the dye diffuses laterally within the plasma membrane (36). This dye 
was recommended and was ideal for the in vivo component of our experiments, but, with the 
confocal microscopes that are commonly used for our in vitro experiments, the spectra of 
excitation of this dye is too high for the lasers used. Furthermore, using the laser that is most 
suited for this dye could also impact cell architecture and distort our images. To address this 
problem, we switched to using Nile Red (excitation 559/emission 636) for the preliminary in 
vitro experiments. NR is a phenoxazone dye that fluoresces intensely in organic solvents and 
hydrophobic lipids. The fluorescence, however, is fully quenched in water and therefore acts as a 
fluorescent hydrophobic probe (37). 
 
In vivo imaging: The tumor mouse model was generated by SC injection of 5×106 M12 or SCP 
cells in PBS into the dorsolumbar region of male and female athymic nude mice (5–6 weeks 
old). The mice were subject to imaging studies when the tumor volume reached a size around 1.0 
cm3. All animal experiments were performed in compliance with VCU’s Institutional Animal 
Care and Use Committee (IACUC). This in vivo experiment used subcutaneous M12 and SCP 
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xenograft tumors in athymic nude mice. Once tumor sizes reached an initial diameter of about 
0.5-1.0cm, the mice were treated intravenously with TCRNs loaded with dye at 2 different 
concentrations. Briefly, using a total of 5 mice per treatment group, animals were injected 
intravenously once in the tail vein or the retro-orbital plexus with approximately 100μl of the dye 
loaded TCRN mixture at various concentrations. At predetermined time points (from 0 to 168 h 
post-injection), these mice were anesthetized with a ~3% isoflurane/oxygen mixture and placed 
in the dark chamber of the IVIS Imaging System 200 Series® in vivo Xenogen® imaging 
instrument. The image was created using the ICG Bkg/ICG and the GFP Bkg/GFP excitation and 
emission filters. The quantitative distribution of TCRNs in the animal was determined by 
fluorescence measurements using vendor software. The total fluorescence efficiency for the 
tumors was measured using a uniform region of interest (ROI) applied to each tumor with 
background from the control value. Image analysis was made using Living Image® software 
v2.60.1. 
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 Chapter 3 
Results 
 
Hypothesis: We propose that TCRNs carrying fluorescent dyes will selectively deposit their 
contents into the cytoplasm and the nucleus of carcinoma cells via the FA/FR interaction, 
producing changes in fluorescent signaling as measured and visualized by in vitro and in vivo 
assays. 
 
Specific Aim 1: To characterize and verify the FR profile of our prostate and breast cancer cell 
lines in order to make meaningful correlations regarding the TCRN’s ability to target our cells 
using this receptor.  
 
Rationale:  Our TCRNs are tagged with a FA moiety in order to exploit the fact that several 
malignant tumors are known to over express the FR. Once we confirm the FR profiles of our 
cells, we can then use the FR/FA interaction to selectively target cells using the TCRNs allowing 
us to attach even greater clinical relevance to our NPs.  
 
In vitro assays verify differential FR expression on breast and prostate cancer cells 
There are many factors influencing the successful delivery of TCRN agents to the cells. 
Our experiments focused on one of those factors, the expression of FRs on the cell surface of the 
prostate and breast cancer cells. TCRNs are designed to use the FR to target cells for delivery of 
their contents. Using multiple protein-based assays, we verified and quantified the presence of 
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the FR on the cells selected for this study. Western results confirm that the FR protein is 
expressed by breast and prostate cancer cells, but to varying degrees. As expected, our results 
showed that the breast cancer cell lines (SCP and MDA-231) express the FR at higher levels than 
the prostate cell lines (M12 and M12-luc) (Figure 5) (12, 24).  It is also worth noting that our 
Western showed that the BJ fibroblasts also strongly expressed the FR. Based on reports in the 
literature, we would not expect that this protein would be expressed primarily on the cell surface, 
although this finding may suggest the expression of the FR in the cytosol since whole cell lysates 
were used. To confirm this, we would need to subject the BJ fibroblast cells to the FACS assay 
and a radioligand binding assay for comparison with our breast cancer prostate cancer cells. 
The results of the Western were further confirmed with a FACS analysis showing the 
prevalence of the FR on the cell surface of intact cells. Flow cytometry is broadly defined as a 
system for measuring and then analyzing the signals that result as particles flow in a liquid 
stream through a beam of light (38). Treated cells are collected and suspended in PBS, and the 
cells are then injected into the flow cytometer. When coupled with fluorescent probes, it enables 
Fluorescence-Activated Cell Sorting (FACS) analysis, which is an ideal tool for sorting 
heterogeneous mixtures of cells based on their cell surface profile. This technology can sort cells 
according to their fluorescent intensity and size. In this FACS analysis, the cells were probed 
with primary antibody against the FR and a secondary antibody flagged with the Alexa 488 
fluorophore. Our FACS analysis for the FR (Figures 6-10, summarized in Table 1) showed that 
the breast cancer cell line (MDA-MB-231) had increased levels of FR when compared with the 
prostate cell lines tested (M12 and M12-luc). Based on this data we would expect that our FA-
labeled TCRNs would be able to interact with these FR-expressing cells in a way that would 
permit them to transport their contents into the cells. Further, we would expect that cells with a 
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Figure 5:  Western Blot Assay Probing for the Folate Receptor (FR). The Western blot 
shows confirmation of the literature’s claim that prostate cancer cell lines (M12L and M12) 
express the FR to a lower degree than the breast cancer cells lines (MDA and SCP). BJ 
fibroblast and ASC cells were included as normal cell comparisons, with minimal expression in 
ASCs and higher expression in BJ. Multiple independent protein isolations from each cell type 
are shown. The loading control used is β-actin. 
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 FACS: Null Control
 
  
Figure 6:  FACS Analysis Showing Poor Alexa Fluor-488 Signal in Null Control. These 
data sets show that M12 prostate cancer cells not probed with any primary or secondary 
antibodies have a very low fluorescent intensity and, therefore, were used to determine 
background signal (i.e., autofluorescence) generated. Similar results were obtained with the 
MDA-MB-231 cell types. 
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 FACS: Negative Control (No 1° Ab)
 
 
Figure 7:  FACS Analysis Showing Poor Alexa Fluor-488 Signal in Negative Control. 
This data set shows M12 prostate cancer cells that were not incubated with a primary antibody 
but were probed with the secondary antibody alone. These results were used to determine 
background signal generated by cells as a consequence of exposure to secondary antibody 
only, as well as any fluorescence associated with experimental manipulation. Similar results 
were obtained with the MDA-MB-231 cell types. 
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 FACS: Positive Control (CD29)
 
 
Figure 8:  FACS Analysis Showing Strong Alexa Fluor-488 Signal in Positive Control. This 
data set shows M12 prostate cancer cells that were probed with anti-CD29 primary antibody 
and the secondary antibody. This sample shows that our FACS assay is optimized and able to 
detect a ubiquitously expressed cell surface antigen when probed. Similar results were obtained 
with the MDA-MB-231 cell types. 
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FACS: Folate Receptor
 
  
Figure 9:  FACS Analysis Showing Weak-Moderate Alexa Fluor-488 Signal in a Probe 
for the FR (M12). This data set shows M12 cells that were probed with the aim of detecting 
cell surface FR. Cells were probed with anti-FR primary antibody and the secondary antibody. 
This experiment shows us the strength of the FR protein expression on the cell surface. 
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 FACS: Folate Receptor
 
 
Figure 10:  FACS Analysis Showing High Alexa Fluor-488 Signal in a Probe for the FR 
(MDA-MB-231). This data set shows MDA-MB-231 cells that were probed with the aim of 
detecting cell surface FR. Cells were probed with anti-FR primary antibody and the secondary 
antibody. This experiment shows us the strength of the FR protein expression on the cell 
surface. 
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 Table 1. Summary of FACS Data
 
 
Table 1:  Summary of Data from FACS Experiments. P1 indicates the percentage of the total 
parent population of cells that were assayed for the receptor in question. P2 indicates the average 
strength of the Alexa 488 signal generated by the cells that were assayed from this subpopulation. 
P3 indicates the percentage of cells that produce a signal that are positive for the receptor being 
probed after accounting for background signal. These results confirm what we see in the western 
and IHC assay characterization of FR. MDAs express FR to a higher degree than the M12’s. 
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stronger FR profile would have a measurably and significantly greater ability to internalize the 
TCRNs than cells with a weaker FR profile. The difference in FR expression was confirmed 
definitively using live cell FACS analysis and less definitively using IF Microscopy (Figure 11). 
Together our data suggests that the FA/FR system will be useful for our TCRNs to deposit their 
fluorescent dyes in FR-expressing carcinoma cells when compared with those cells that express 
lower levels of FRs. 
In our FACs assay, we also probed for the prostate specific membrane antigen (PSMA) 
(see Table 1). Recent studies have shown that this membrane bound protein can also be used by 
cells to transport FA into cells (39). The presence of this protein in our cells could potentially 
influence the uptake of our FA conjugated TCRNs, especially with respect to our prostate cancer 
cells that show a reduced level of FR compared to the breast cancer lines. While we did not 
perform any experiments that would specifically target this protein using the TCRNs, it is 
important to factor its expression into any results that make use of the FA/FR interaction as 
PSMA can also internalize FA. The presence of this protein in our M12 cells cells could 
potentially lend greater weight to the importance of the FA moiety on our TCRNs and provide an 
alternative method for exploiting this interaction in other cells, especially prostate cancer cells. 
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Figure 11:  Immunocytochemistry Assay Showing Folate Receptor expression in M12 
prostate and MDA-MB-231 breast cancer cells. Shown, imaged at 60x magnification, is a 
stronger fluorescent signal produced by cells when probed for the FR. FR protein is detected 
in the 3 cell lines but seems to be slightly stronger in MDA-231 cells. Control cells were 
probed with 2° antibody alone. 
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 Specific Aim 2: To demonstrate TCRN dye delivery to cells correlating TCRN function with the 
FR using differences in fluorescent signaling within the cytoplasm and the nucleus of our cells 
 
Rationale: Because there are studies that suggest that the TCRNs can carry and deposit their 
contents into the nucleus of cells grown in vitro, we believe that if this data can be verified in 
additional cell lines using different agents in vitro and then in vivo we can then infer that the 
TCRNs have the potential to be used to carry chemotherapeutic agents in a clinical setting. 
 
In vitro cytotoxicity suggests optimal TCRN dose 
In general, any novel NP is considered to be a potential biological hazard, making it 
critical to evaluate any potential in vitro cytotoxicity related to the TCRNs that could interfere 
with our study. Once safety can be demonstrated using TCRNs carrying biologically inert dyes, 
then we can infer that the TCRNs may be used to carry other more biologically active agents that 
may have their own cytotoxic effects, which will also enable us to restrict our interpretations 
regarding efficacy to the agent and not to the carrier. Using a dose response curve, we were able 
to determine an optimal concentration of the TCRNs that enabled normal cell proliferation, 
which suggests a starting point for an in vivo dosage for assessing toxicity in mice.    
This experiment provided optimal conditions for cell growth in the presence of the dye-
loaded TCRNs. The experiment shows that the optimal dilution of dye for cell survival of both 
cell types was the 1:100 dilution of the nanoparticles, which corresponds to the 0.4µg/ml 
treatment for DiR and the 0.034µg/ml treatment for NR (Figures 12, 13). Cell survival was also 
highest at 24 and 48 hrs post inoculation. Our data demonstrate that TCRNs loaded with dye do 
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Figure 12:  Percent viability of SCP breast cancer cells treated with dye loaded TCRNs over 
time. These graphs show that the highest dosage of the dye loaded TCRNs that can support cell 
growth over time without adverse affects is 0.034µg/ml (Nile Red) and 0.4µg/ml (DiR). This 
suggests a dose dependent toxic affect associated with the TCRNs in this cell line.  
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Figure 13:  Percent viability of M12 prostate cancer cells treated with dye loaded TCRNs 
over time. These graphs show that the highest dosage of the dye loaded TCRNs that can 
support cell growth over time without adverse affects is 0.034µg/ml (Nile Red) and 0.4µg/ml 
(DiR). This suggests a dose dependent toxic affect associated with the TCRNs in these cells. 
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impact the survival of both the SCP and the M12 cell lines and that there is a toxic effect related 
to the TCRNs especially at the higher concentrations of dye. The results indicate that the highest 
concentration of DiR for both cell types is 0.4μg/ml and 0.034μg/ml for NR. These values 
correspond to NP concentrations of 30μg/ml and 0.3μg/ml respectively. 
 
Confocal Microscopy shows nuclear association of TCRN dye. 
The confocal assay of this experiment was complicated by many technical challenges. 
The TCRNs have a very short shelf life (approximately 3 weeks) and so many of the in vitro and 
in vivo experiments had to be performed at the same time once the TCRNs were made. There 
were also technical issues associated with the confocal microscopy, which was discovered after 
processing the images. The use of the Leica microscope provided little, if any, capability to 
distinguish subcellular localization (Figure 14, lower panels), while the Zeiss confocal 
microscope showed definitive localization of the dye-loaded TCRNs Figure 14, upper panels). 
Further examination of the confocal images suggested that, at a minimum, the TCRNs can enter 
cells and deposit their contents into the cytoplasm. It appears that they travel and associate with 
the nucleus and possibly deposit a fraction of their contents into the nucleus (Figure 14). The 
peak effect noted in this experiment parallels the survival experiment and shows that the 
strongest fluorescent signal for the NR dye occurs in the 1:100 dilution between 24-72 hours post 
incubation with the TCRNs. 
 
In vivo parenterally administered TCRNs fail to show tissue specificity.  
Extrapolating in vivo dosing from our in vitro experiments was a challenge, but, in this 
experiment, it was useful to correlate the concentration of the TCRNs with the dye within the 
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Figure 14:  Zeiss and Leica confocal images of SCP28 cells grown in vitro at 1:100 dilution 
of NR loaded TCRNs and 48hrs post treatment. Representative images of the same cells taken 
with 2 different microscope systems showing the qualitative differences noted between the two 
systems. The top images were obtained using the Zeis microscope. Nuclei are stained with DAPI 
and nucleus is dotted with red staining likely resulting from deposition of NiR dye. Magnified 
image is shown to the right, with punctuate TCRNs localizing in the perinuclear region of the 
cell. The bottom images were obtained using the Leica microscope. The image shows that the 
nuclei are stained with DAPI and that those nuclei staining red may be the result of deposition of 
NiR dye, although this is unclear. This data suggests that there were notable differences in cells 
viewed under Leica vs. Zeis confocal microscopes and that TCRNs are localized near the nucleus 
but there is no clear evidence of nuclear delivery. 
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blood stream with the concentrations of TCRNs that are used in the media in our in vitro 
cytotoxicity experiments. Blood volume in animals is estimated using the following formula: 
body weight (kg) x 7% = total blood volume (L) (40). For a typical mouse of about 20-40g, we 
can calculate a total blood volume of 2.5mls.  In our initial in vivo experiments, we delivered the 
dye-loaded TCRN in a 0.1ml total volume.  We also noted that the highest concentration of the 
dye/TCRN solution that could be given to the animals without noticeable and consistent toxic 
effects was 36µg/ml of DIR dye and 30mg/ml TCRN NPs. In a 20g mouse (blood vol ~1.5mls), 
this translates to a dose of roughly 180µg/kg of dye or a blood concentration of dye equal to 
2.4µg/ml. The lowest treatment administered in this experiment corresponds to a dosage of 
60µg/kg of dye or a blood concentration of dye equal to 0.8μg/ml, which parallels studies of 
these classes of drugs suggest as being well within a tolerable range.  
Based on our in vitro data and the literature, we predicted that TCRNs carrying 
fluorescent dyes would selectively target tumor cells, differentially depositing their contents into 
the nucleus of carcinoma cells in a way that produces changes in fluorescent signaling. Here we 
are only able to determine if dye is selectively deposited into the tumor tissue, and we infer from 
our confocal studies that if the dye can be selectively focused in the tumor tissue, then it will 
deliver its contents to the cells in the same manner noted in confocal microscopy. We measured 
the fluorescent signal in the tumor using in vivo bioluminescent/fluorescent imaging with XIT at 
various time points for one week. We found that the TCRNs are clearly being deposited in the 
animals and that the particles persist in tissue without significant selectivity for the tumor tissue 
(shown in Figures 15 and 16, and quantified in Figure 17).  
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Figure 15: Representative imaging of TCRN fluorescent signal (DiR) using Xenogen 
Technology. These images represent fluorescent signal from the nanoparticles after 1 week of 
incubation in athymic nude mice, either without tumor (Females w/o Tumors) or after injection 
with M12 prostate cancer cells (Males w/ Tumors). 
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Figure 16:  Representative Xenogen images of female mice with tumors measured at 7 
days. The fluorescent signal of xenograft tumors measured in female is shown for D-luciferase 
(tumor fluorescence) and DiR (TCRN fluorescence), showing minimal overlap of nanoparticle 
and tumor. 
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Figure 17:  Fluorescent signal measured over time using Xenogen Imaging Technology. 
These graphs show the fluorescent signal of xenograft tumors measured in female (top) and male 
(bottom) mice and recorded over time for 6 groups. The groups represent the various doses of 
DiR dye delivered by the TCRNs. Mice with tumors (T+) are compared with mice lacking 
tumors (T-). This data suggests that tissue deposition occurs without apparent selection of tumor 
tissue. 
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The in vivo Xenogen studies were subjected to complex statistical analysis using 
sophisticated regression analysis with multiple variables and it was determined that the 
differences noted between the treated and non treated animals was not significant. The strength 
of our in vitro conclusions derives from the fact that we confirmed the results in one assay using 
complementary assays. Statistical analysis for most of our in vitro experiments was moderately 
limited because of the lack replicate experiments for the confocal and FACS analyses and 
because Western densitometry is historically not quantitative. Importantly, the Western assays 
were repeated, showing remarkable similarity in the overall expression levels for each cell type, 
including breast and prostate cancer and the 2 normal cell types, BJ fibroblasts and ASCs. In 
general, our results clearly show that the FR is expressed at higher levels in breast tumor cells 
and to some degree in prostate tumor cells using 3 different techniques. The in vivo results, while 
not statistically significant in terms of TCRN-tumor co-localization, were important and 
definitive in showing localization of the TCRN in the animal and retention of the nanoparticle 
for more than 5 days without liver toxicity and/or excretion by the mice. Taken together, our 
results suggest that TCRNs have the ability to target the FR in tumor cells and be effectively 
delivered at or near the nucleus of the cells, while showing stability after delivery into tumor 
bearing animals.  
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 Chapter 4 
Discussion 
 
Even the briefest review of the current literature related to nantotechnology will convince 
one that this field is explosive, one that is ripe with potential for advances especially in the area 
of biomedical applications. Because the field is so young, much work needs to be done using in 
vivo systems. Although ambitious, our proposal tried to confirm the in vitro experiments 
associated with the TCRNs with in vivo experiments. There is much that can be said about these 
NPs after our experiments, but there is still much more that needs to be done before definitive 
conclusions can be made about them.  
Our TCRN was tagged with a FA moiety in order to exploit the fact that many cancers 
over-express FRs while most normal tissues express low to negligible levels. This FA/FR 
interaction would help to show the clinical significance of the TCRNs. Furthermore, the 
literature confirms that the over-expression of FRs on the surface of breast cancer cells is a 
strong predictor of poor outcome in patients with breast cancer (12, 41), and so we would 
anticipate that the SCP28 metastatic breast cancer cell line and the cell line from which it was 
created (MDA-MB-231) would express higher levels of FR than the M12 prostate cancer cell 
line.  
Our experiments using Western and FACS confirm the variable expression of the FR in 
all of our cells, while the confocal immunocytochemistry further verifies the presence of FR on 
the cell surface in our tumor cell lines. While we unexpectedly show increased expression of FR 
in the BJ fibroblast cells, previous results using normal cell types indicate that FR expression is 
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luminal rather than on the cell surface. That said, additional experiments using FACS would 
confirm this and ultimately lend credence to our assertion that FR, while expressed in normal 
cells, would not be targeted by our TCRNs as FR expression is not on the surface of our cells. 
Additionally, we found that FR is a cell surface protein that is difficult to isolate without 
disrupting its confirmation, which is necessary for detection using our primary antibody. We 
attribute much of the background observed in our FR Westerns to dimerization or fragmentation 
of the FR protein or even FR complexing with other proteins. We plan to further confirm our 
results using other antibodies.  
Our FACS and Western assays also independently confirm the expression of the PSMA 
protein in the M12 prostate cancer cell lines, which may, based on the literature (39), also be 
exploited to bring FA into cells. By inference, this protein will be able to complement the FR in 
transporting the FA tagged nanoparticples into the cell. Further characterization of the PSMA 
protein using confocal-based immunocytochemistry will be done to determine PSMA’s ability to 
be targeted by our TCRNs.  
To further strengthen all of our assays, we plan to repeat this characterization using M12 
and MDA-231 cells that have been engineered to over-express FR or with cells expressing a 
dominant-negative mutant variant of the FR protein to reduce FR expression and function. Using 
these FR engineered cells, we can begin to more reliably track the movement of the TCRNs into 
the cells with confocal analysis, comparing high FR cells with cells that have either intermediate 
FR expression or low FR expression. If the TCRNs perform as expected, we expect to see a 
difference in the speed of dye uptake by the cells, as well as perhaps more clear evidence of 
nuclear deposition. We will then track the TCRN uptake using Live Cell Confocal Microscopy 
and record the timing of cellular uptake and association with the nucleus of the cell. To 
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maximize the expression of the FR on the cell surface, we can also grow cells for a period of 
time in FA deficient media, thereby allowing for more exposed, uncomplexed FR on the cell 
surface.  
Our confocal experiments indicate that the Nile Red dye loaded FA-labeled TCRNs can 
be taken up by the cells and are able to associate with the nucleus while maintaining cell 
viability. Preliminary results suggest very little, if any, nuclear deposition of dye into the cells, 
yet there is significant association with the nucleus rather than just complete cytoplasmic 
distribution. To further confirm specific subcellular delivery of the dye rather than simple 
nuclear association of the dye/NPs, TCRNs have been designed to be tagged with Cy5 dye. This 
TCRN labeling, together with the Nile Red or DiR internally loaded dye, would allow tracking 
of the TCRN versus when and where the dye is released within the cell.  
We find that the cells have a dose-dependent tolerance of the TCRNs, with optimal 
concentrations consistent with what translates into tolerable and detectable doses in vivo. Our 
results also show that cells do not survive well with higher concentrations of the TCRNs; yet our 
experiments do not distinguish between the effects of the TRCN, the dye, or the combination of 
dye and NP. To determine the relative contribution of each of these components we would need 
to repeat the cytotoxicity experiments to include treatments with 1) the dyes alone 2) the empty 
(dye free) TCRNs and 3) the dye loaded TCRNs without the FA moiety. Also, since the TCRNs 
are responsive to changes in pH, we plan to vary the pH to confirm this function and to 
investigate the influence pH has on the TCRN’s ability to affect the cell at various 
concentrations.  
We can also conclude from the in vivo experiments that the TCRNs can safely be 
administered to animals intravenously and that they retain their ability to deposit their contents in 
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tissues in an in vivo environment. We find that the TCRNs loaded with DiR are retained in the 
animal for up to 7 days without being excreted through typical channels with no association with 
the liver. We also observe tumor fluorescence using the SCP26 cells (luciferase), and after 
TCRN injection, there is only modest overlap of the DiR from the TCRN and the luciferase from 
the SCP26 cells. In the prostate cancer cells that were unlabeled (M12), we did find some 
overlap with the tumor in a few of our mice, suggesting that the colocalization of TCRN with 
tumor may be tumor-specific or that it could be dependent on the method and efficiency of 
injection (see below). While much more work needs to be done, our efforts open the possibility 
for further work with these NPs in future in vivo studies, providing more selective targeting after 
alteration of the TCRN structure.   
Since the clinical relevance of the TCRNs hinges on their ability to specifically localize 
to the tumor tissue in live animals, we propose modifications of the in vivo component of our 
experiment. First, the selection of cells for the xenograft tumor is critical. We discovered that the 
SCP26 cells were over engineered with respect to their ability to express 2 kinds of luciferase 
and a GFP, and the knockdown of Smad4 in these cells is achieved by expression of a shRNA 
with GFP as selection marker, so the cells will constantly express GFP and thereby have green 
fluorescence (34). Even though the DiR dye has a spectrum that is sufficiently distinct from the 
GFP and we are able to specify filters that target the DiR, our cells may still produce background 
levels of fluorescence that may confound the results. Because of this, we plan to use cells that 
only express luciferase in addition to their increased expression of FR (MDA-MB-231-
luciferase), so that we will be able to control the luciferase fluorescence with the addition of D-
luciferin. This fluorescent signal would enable us to restrict our ROI to the tumor and reduce 
extraneous tissue that could dilute our signal. Our expectation is that this should enable us to see 
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a measurably stronger signal in the cells with a higher expression of FR compared to those that 
have their expression knocked down. To determine the precise location within the tumor, as well 
as within the tumor cells, we would further evaluate the deposition of TCRNs by employing 
confocal microscopy on the excised tumor tissue to detect both the dye from the TCRN and 
luciferase.  
We found that the administration of the TCRNs intravenously was quite tedious for our in 
vivo studies. Since the Xenogen imaging chamber makes intravenous injections extremely 
difficult, we needed to find a protocol that permits injections to take place outside of the chamber 
in a more controlled environment to optimize success. This required us to eliminate the first post-
treatment Xenogen reading (immediately post injection), which, based on our results, does not 
show much of a measureable difference in fluorescent signal in any of our experiments. The loss 
of this data point would not be as significant as the loss of animals incurred from rushed 
injections resulting from perivascular leakage of drug, which often occurred during our 
experiment. A clear intravenous injection also assures us that the dosage delivered is accurate 
and free from extravascular background signaling. Preliminary tests using either tail vein and/or 
retro-orbital injection methods both showed significant promise when done outside of the 
Xenogen staging area.  
In addition, we found significant bleeding of signal from one animal to another adjacent 
animal as a result of high fluorescent signals from neighboring tumors. This confounded some 
results where some tumors showed much higher signals than was to be expected based on tumor 
size. Thus, shielding individual animal during imaging with a barrier divider will be done, which 
will prevent radiant signal from adjacent animals, a problem we encountered during our imaging. 
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Clearly, the ultimate confirmation of TCRN efficacy will come when the NPs are loaded 
with an actual chemotherapeutic agent and subjected to the same in vitro and in vivo 
experiments. These results, combined with our in vitro and in vivo preliminary data, will allow 
correlation of cytotoxicity and tumor burden reduction with drug concentration, while additional 
experiments using cells with alterations in FR expression will prove the importance of direct 
tumor cell targeting in a living system.  
In conclusion, despite a lack of specific nuclear deposition of TCRN contents in tumor 
cells, our data are quite encouraging and suggest that the TCRNs have the potential to target 
tumor cells using the FR and that the TCRNs are stable in vitro and in vivo. By refining and 
expanding our in vitro experiments, we will be able to exercise greater control over all of these 
variables in future experiments, translating these in vitro results to more definitive results in vivo 
in order to determine the value of TCRNs in a therapeutic setting. In the end, if we can only 
demonstrate nuclear association and not delivery, this finding would still be significant and 
would suggest needed alteration in the TCRN to trigger nuclear delivery. Targeting FR-
expressing carcinoma cells and focusing drug delivery to the nucleus will ultimately result in 
greater efficacy with lower drug concentrations, especially with therapeutic compounds that 
target and damage DNA as their mode of action. 
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